Trodelvy
Gilead Bolsters Trodelvy in Triple-Negative Breast Cancer With Practice-Changing Keytruda Combo Win
Gilead Sciences; Trodelvy; Keytruda; triple-negative breast cancer; TNBC; antibody-drug conjugate; immunotherapy; progression-free survival; ASCO 2025; phase 3 trial; practice-changing; combination therapy
Gilead eyes earlier use of Trodelvy in TNBC as Phase III hits key goal
Trodelvy, Triple Negative Breast Neoplasms, Metastatic to, Keytruda, Overall Survival
Gilead Exceeds COVID-19 Drug Sales Projections, Faces $1.75 Billion Loss on Trodelvy Trial Failure
Gilead, COVID-19, Veklury, Trodelvy, drug sales, clinical trial failure
Gilead Withdraws US Indication for Sacituzumab Govitecan in Metastatic Urothelial Cancer
Sacituzumab Govitecan, Trodelvy, Bladder Cancer, Urothelial Cancer, Gilead Sciences, FDA, Accelerated Approval Withdrawal
Gilead Withdraws Trodelvy for Bladder Cancer in US After Confirmatory Trial Failure
Gilead Sciences, Trodelvy, bladder cancer, urothelial carcinoma, FDA, accelerated approval, drug withdrawal
AstraZeneca and Gilead Explore TROP2 ADCs in Lung Cancer, Seeking Pathways to Approval
TROP2 ADCs, Lung Cancer, AstraZeneca, Gilead, Datopotamab Deruxtecan, Trodelvy, Non-Small Cell Lung Cancer (NSCLC)
Gilead’s Trodelvy Fails to Meet Primary Endpoint in Confirmatory Trial for Urothelial Cancer
Gilead Sciences, Trodelvy, urothelial cancer, TROPiCS-04 study, overall survival, antibody-drug conjugate, oncology, clinical trials, FDA approval
Gilead’s Trodelvy Fails to Meet Primary Endpoint in Lung Cancer Trial, but Shows Promise in Subgroup Analysis ###
Gilead Sciences, Trodelvy, Lung Cancer, ASCO, FDA, Clinical Trials, Oncology, Immunotherapy, Trop-2 Directed Antibody-Drug Conjugate
Gilead’s Strategic Focus: CymaBay Liver Drug, Trodelvy Data, and Long-Acting PrEP in 2023
Gilead, CymaBay, liver drug, Trodelvy, readouts, long-acting PrEP, 2023, strategic focus.
Gilead Sciences Receives $210 Million Venture Capital Funding to Expand Trodelvy’s Application in Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Carcinoma, Capital, Trodelvy, Trodelvy’s, Application procedure